N4 Pharma has acquired an exclusive option to file a range of draft patent applications prepared by OPAL IP Limited for the purpose of reformulating certain existing drugs whose patents have already expired or are shortly to expire. N4 Pharma has the exclusive right to select and evaluate those draft patent applications in OPAL IP’s portfolio which N4 Pharma believes to be the most commercially valuable.
N4 Pharma has also acquired the exclusive rights to commercialise two patent applications for its vaccines division. The first concerns novel silica nano particles for certain sub-unit vaccines used for a number of diseases, including Hepatitis B, for which N4 Pharma has registered the trademark Nuvac® in the UK. The second concerns the delivery of DNA and mRNA vaccines, for which N4 Pharma has registered the trademark Nuvec® in the UK.